Category: Corona Virus

Page 15«..10..14151617..2030..»

What the Historic Infusion of Federal Pandemic Aid Did for Schools – Education Week

June 29, 2024

The largest federal emergency school aid in history boosted learning recovery from the pandemic, two new studies findbut the benefits have been uneven and nowhere near enough to get students fully back on track.

In March 2020, shortly after the COVID-19 pandemic shuttered schools nationwide, Congress passed the first of three massive rounds of K-12 aid that would ultimately total more than $190 billion. At the time, no one knew how long communities would be in lockdown, how long students would attend classes remotely, or the long-term effects of academic disruption, health problems, social isolation, and trauma on students learning progress.

With several years of hindsight, we now know children have paid a brutal cost for that disruption: reading and math performance at historic lows , student mental health problems at historic highs , and chronic absenteeism still topping 1 in 4 students nationwide.

As school districts approach the end of spending ESSER funds, two new studiesconducted separately but jointly released Wednesday morninganalyzed the effect of the grants on math and language arts test scores of more than 5,000 districts in grades 3-8 across about 30 states, during the 2022-23 school year.

Both studiesone released by the National Center for Analysis of Longitudinal Data in Education Research (CALDER) at the American Institutes of Research and the other by Harvard Universitys Center for Education Policy Research and the Educational Opportunity Project at Stanford University found the grants did accelerate academic recovery in mathabout six days worth of learning progress for every additional $1,000 their districts received from federal aid.

Both studies found minimal benefit for reading from ESSER but an increase of about 0.008 of a standard deviationroughly 3 percent of a school yearon students math performance for every additional $1,000 districts received in federal recovery money.

That means federal aid accounts for about 35 percent of the total learning progress students regained from the end of 2022 to the end of 2023, according to Dan Goldhaber, the CALDER director and a co-author of one of the studies.

ESSER funding did actually move the needle of student achievement, Goldhaber said, but then you get into, did it move it enough? Well, it certainly did not bring student achievement back to the 2019 levelsit wasnt even close to that. A very strong effect for some and not much for everybody else ... I think that is a little bit what we are seeing.

While $1,000 of aid provided roughly the same bang for your buck in districts of all income levels, Stanford University professor Sean Reardon, the co-author of one of the studies, said the net effect of the investment was much, much larger in the high-poverty districts than the low-poverty districts, not because they got more per dollar but because they got a lot more dollars which has somewhat reduced the economic achievement gap among districts.

However, in districts of similar poverty levels, Goldhaber noted the ones serving fewer Black or Hispanic students and those located in towns (as defined by the Census Bureau) had slightly bigger learning increases from the aid. Its not clear why, though communities of color were disproportionately harmed during the pandemic.

The two studies findings are in line with the return on investment from district spending generally before the pandemic, based on a 2023 research analysis.

Schools would have to spend another $9,000 to $13,000 per student to bring students fully back on track academically from the remaining learning gaps in language arts and math as of 2023, Goldhaber estimated.

ESSERs effectiveness was limited, researchers say, by competing priorities for the grants and inequities in how the money was distributed.

When the American Rescue plan passed, nobody even knew the magnitude of the achievement loss, said Harvard economist and study co-author Thomas Kane. The money at the time was primarily about trying to get schools reopened.

Hermiston, Ore., public schools, for example, were among the first to close when COVID-19 reached American shores, and the district remained in remote instruction through most of the 2020-21 school year. Recouping lost academic progress came second to just getting more than 5,600 kids back on campus, according to Superintendent Tricia Mooney.

When ESSER I came out [in 2020], we were all very much drinking from a fire hose, trying to figure out how we were going to get students through the pandemic, Mooney said. We really looked at what investments we could make that werent going to create long-term financial responsibilities.

Because they knew ESSER would be limited-time aid, Mooney said her district dedicated the money first to capital projects like a new HVAC system and later to mental health services and a comprehensive summer school program for students who need extra support.

Those nonacademic benefits should be kept in mind although they couldnt be included in the two current studies, Reardon said. Even though [3 percent of a school year effect per $1,000] doesnt sound like a lot, when you calculate the social returns and the economic returns to improved academic performance, that much improvement is worth slightly more than $1,000 in lifetime earnings, and there are other social benefits like lower crime, Reardon said. Its still a net positive from a cost-benefit analysis in terms of social returns.

After three years and with nearly 300 fewer students, Mooney said her community has vowed to sustain the summer enrichment past the federal funding cliff.

Mooney said the money helped the district reopen quicker, and the summer program has been critically important to bolster language skills in the heavily Hispanic district. But Hermiston still struggles to reengage the 40 percent of students who dont attend regularly, and the academic outlook remains grim, with less than a third of students proficient in reading and only 14 percent proficient in math in 2022.

ESSER was distributed to states and districts based on the standard funding formula for Title I grants to schools serving low-income students.

We were pushing through $175 billion in federal aid through pipes that were meant to carry $16 billion in aid, Kane said, and so whatever quirks there were [in the normal Title I funding formula] got multiplied by 10 or more.

For example, a high-poverty district in New Hampshireone of the small rural states that receives a set minimum Title I grantmight under normal conditions receive $500 more per student than a district with similar poverty in neighboring Massachusetts. But for the recovery aid, this difference was closer to $5,000 per student, Kane said.

Its impossible to say at this point what academic interventions drove learning recovery, because neither of the studies looked at exactly how districts spent their ESSER money. In part, thats because besides requiring that districts spend at least 20 percent of their grants on learning recovery, states differed widely in how they asked districts to report their spending. Moreover, districts still have until Sept. 30 to commit their grant spending and through the end of January 2025 to finish spending the money.

Based on what we saw between 22 and 23, we would predict that therell be an awful lot of districts that are still behind when 24 [test results] come back, Kane said. We ought to be asking ourselves, what more is it going to take? ... Because the recovery is unlikely to be over.

Originally posted here:

What the Historic Infusion of Federal Pandemic Aid Did for Schools - Education Week

COVID-19: Get Tested – Wisconsin Department of Health Services

June 29, 2024

Test for COVID-19 if you were exposed to COVID-19 or if you have COVID-19 symptoms.

While you wait for your COVID-19 test results, stay home and monitor your symptoms to protect yourself and others.

For more information about COVID-19 testing, visit: COVID-19 Testing: You Need to Know | CDC (Centers for Disease Control and Prevention)

There are many ways test for COVID-19 in Wisconsin:

If your COVID-19 test is positive, it means the virus was detected and you have or recently had an infection. If you have symptoms, stay home and away from others (including people you live with who are not sick). Take steps to prevent spreading COVID-19. You can go back to your normal activities when, for at least 24 hours:

If your COVID-19 test is negative, it means the test did not detect the virus and you likely do not have COVID-19.

For more information about what your COVID-19 test result means, visit: COVID-19 Testing: What You Need to Know | CDC

Read this article:

COVID-19: Get Tested - Wisconsin Department of Health Services

SARS-CoV-2 antigenemia and RNAemia in association with disease severity in patients with COVID-19 | Scientific … – Nature.com

June 29, 2024

The authors reporting experiments on the use of human and/or human tissue samples were all experiments conducted in accordance with relevant guidelines and regulations. Informed consent was obtained from all subjects and/or legal guardians. The study was conducted in accordance with relevant guidelines and regulations for all methods.

In our hospital, we performed a prospective cohort study from June 21, 2020, to September 30, 2023, with patients who possibly had COVID-19 using a preformed case record form. We enrolled 119 patients with confirmed COVID-19 who gave consent for comprehensive use of specimens, admitted from June 21, 2020 to October 22, 2021 at Chosun University Hospital, South Korea. Our aim was to examine the clinical association of antigenemia and RNAemia. All selected patients were clinically confirmed to be SARS-CoV-2 positive using more than one diagnostic methods, including real-time reverse transcriptase polymerase chain reaction (qRT-PCR) with the confirmation of more than two target genes, cell culture, or afourfold increase or seroconversion in terms of SARS-CoV-2 antibody titer (enzyme-linked immunosorbent assay [ELISA] or indirect immunofluorescence antibody assay). Moreover, 81 serum/plasma samples of healthy individuals without clinical symptoms, no history of COVID-19, and negative nasopharyngeal qRT-PCR results were used as control samples for the sensitivity assay.

Peripheral blood was collected from all patients and 200 L serum/plasma samples from fresh blood were used for ribonucleic acid (RNA) extraction. Concurrently self-collected sputum samples collected from the patients were diluted in phosphate-buffered saline (PBS), mixed by vortexing and pulse-centrifuged for 1min, and 200 L supernatant was subjected to RNA extraction. Nasopharynx swabs were directly collected into the commercial UTM kits containing 1mL of a viral transport medium (NobleBio, Oldenzaal, The Netherlands) by a physician, and 200 L were employed for RNA extraction. The viral RNA was extracted by Real-prep Viral DNA/RNA Kit (Biosewoom, Seoul, South Korea) using a fully automated instrument (Real-Prep system, Biosewoom).

For the qRT-PCR assay of the nucleocapsid protein (NP) gene, primers and probes were designed in-house, nCov-NP_572F (5-GCAACAGTTCAAGAAATTC-3), nCov-NP_687R (5-CTGGTTCAATCTGTCAAG-3), and nCov-NP_661P (5-FAM-AAGCAAGAGCAGCATCACCG-BHQ1-3). Thermal cycling was performed as follows: 50C for 10min for reverse transcription, one cycle of 95C for 30s for preincubation, 95C for 5s at 57C for amplification, and 45 cycles for data detection. For the target genes E (encoding envelope protein) and RdRp (encoding RNA-dependent RNA polymerase), the Kogene Kit (Kogene Biotech Co., Ltd., Seoul, South Korea) and SD Kit (SD Biotechnologies Co., Ltd., Seoul, South Korea) were used, and amplification was performed according to the manufacturers instructions. For the NP target, qRT-PCR was performed in an Exicycler 96 Real-Time Quantitative Thermal Block (Bioneer, Smiths Parish, Bermuda), and for Kogene and SD kits, the CFX96 Touch Real-Time PCR Detection System (Biorad, Hercules, CA, USA) was used. Cycle threshold (Ct) values were set to40 for the reference gene and were assumed to denote a positive result.

For the identification of SARS-CoV-2 in culture, monolayers of Vero E6 cells were cultured in Dulbeccos modified Eagles medium supplemented with 10% of fetal bovine serum and a 1penicillinstreptomycin antibiotic solution (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) in an atmosphere containing 5% of CO2 at 37C. Then, 200 L of an unfrozen swab sample in viral transport medium (UTM kit, NobleBio) diluted with 1mL of Dulbeccos phosphate-buffered saline (Welgene, Taipei, Fujian, China) was inoculated to the monolayer of cultured Vero cells. After two passages, viral proliferation was confirmed by qRT-PCR with a confirmatory Ct value<20 or an indirect immunofluorescence assay using in-house SARS-CoV-2 antigen slides. Meanwhile, inoculated cells were examined daily for cytopathic effects, as described for SARS-CoV and MERS-CoV in other studies16,17.

The nucleocapsid protein (N) antigenemia assay of patients with and without COVID-19 was carried out using single molecule array (SIMOA) technology with paramagnetic microbeadsbased sandwich ELISA. The SIMOA SARS-CoV-2 N Protein Advantage kit assay (Quanterix Corp, Boston, MA, USA, PN/103806) is a digital immunoassay that quantitatively measures the SARS-CoV-2 nucleocapsid protein in human serum and plasma. Plasma or serum obtained from fresh blood was frozen after aliquoting to minimize protein degradation due to freezethaw cycles and thawed at room temperature before use for antigenemia assay. Briefly, each well of 96-well ELISA microplates (Quanterix plates) was loaded with 4dilution of plasma or serum and assayed in Simoa HD-X instrument (Quanterix) using a twostep immunoassay. For detection, incubation was performed with the target antibody coated with paramagnetic beads, sample, and biotinylated antibody (SIMOA Guide Quanterix). The nucleocapsid protein present in the sample was captured using antibody-coated beads bound to the biotinylated antibody, and detected simultaneously as described previously18,19.

Indirect ELISA for SARS-CoV-2 was performed using a recombinant nucleocapsid protein (Bioapp. Inc., Pohang, South Korea) to determine serological titers of immunoglobulin G (IgG), immunoglobulin M (IgM), and total antibodies. Frozen serum samples were thawed at room temperature and used for indirect ELISA. In brief, 100 L of 2g/mL recombinant SARS-CoV-2 nucleocapsid protein (Bioapp. Inc.) was coated in a 96-well ELISA microplate (Thermo Fisher Scientific) with carbonate-bicarbonate buffer, with overnight incubation at 4C. The ELISA plates were washed with PBS containing 0.05% Tween 20, followed by 2-h blocking at 37C with 5% skim milk in blocking buffer. The plates were further washed incubated for another 2h at 37C with the serum samples diluted 100-fold in blocking buffer. After washing, a secondary antibody (horseradish peroxidase-conjugated goat anti-human IgG antibody [1:6000, Invitrogen, Thermo Fisher Scientific, Cat A18805], anti-human IgM antibody [1:3000, Invitrogen, Thermo Fisher Scientific, Cat 31415], or anti-human total-antibody antibody [1:40,000; Thermo Fisher Scientific, Cat 31418]) was added, and incubated again for another 1h at 37C. The plates were further washed and 50 L of the 3,35,5-tetramethylbenzidine substrate (Sigma-Aldrich, St. Louis, MO, USA) was added and incubated at room temperature (2030C) for 30min in dark. Moreover, 25 L of 1M H2SO4 was added for arresting the reaction and the optical density was measured using an Epoch two microplate spectrophotometer (Kitchener, ON, Canada) at 450nm (OD450). The cutoff values and positivity for SARS-CoV-2 were set as described previously20.

Statistical analyses were performed using MedCalc 20013 software (Ostend, Belgium), and IBM SPSS Statistics for Windows, version 26.0. (IBM Corp., Armonk, NY, USA), and GraphPad Prism 9 (San Diego, CA, USA). The sensitivity, specificity, and accuracy of the test were evaluated using receiver operating characteristic (ROC) curve analysis. Confidence intervals for sensitivity, specificity and accuracy are exact ClopperPearson confidence intervals21. To determine the 40-day survival rate, KaplanMeier survival analysis was conducted based on the antigenemia concentration. Quantitative variables are presented as meanstandard deviation and n (%) for normally distributed variables. Mean values were compared using t-tests for continuous variables and were found to be normally distributed. P-values comparing patients with COVID-19 with evidence of antigenemia and RNAemia to those without antigenemia and RNAemia were calculated using the MannWhitney U or Fishers exact test, as appropriate.

More:

SARS-CoV-2 antigenemia and RNAemia in association with disease severity in patients with COVID-19 | Scientific ... - Nature.com

Impact of vaccine coverage and disruption to health services on COVID-19 in Ukraine | Scientific Reports – Nature.com

June 29, 2024

Figure1 shows the modelled epidemic around the time of the start of the war in early 2022 fitted to observed data to estimate the reduction in population contacts. In the base case scenario where masks are 60% effective, the best fit to data shows a reduction in contacts of 33% in the first period and 47% to 70% in the second period (Fig.1). Otherwise, in the case of masks being effective at 40%, the best fit resulted in a reduction in contacts of 40% in the first period and 53% to 73% in the second period.

Model fit to clinical case notification data (COVID-19 incidence notification data) between 6 January 2022 and 25 February 2022, with masks 60% effective. The vertical lines represent the dates of policy changes. 6 January is the start of the Omicron wave; 617 January is the first pre-war period with the implemented restrictions policy17,18; 1825 January is the second pre-war period where the reduction in contacts increases with the additional policy of closure of public transports and enforced mask use in all public spaces17,18; 25 February represent the start of the war, where vaccine rollout and contact tracing stops.

The modelled incidence of deaths in the same period, using reported rates from European and US studies, of 0.3%, 0.08%, and 0.07% in unvaccinated, vaccinated with two and three doses respectively (Fig.2 green line), is much lower than rates reported in Ukraine (Fig.2 blue line). Multiplying those numbers by 5 times, produces a much better fit (Fig.2 red line), suggesting an under report of case numbers or higher death rates for Ukraine compared to the ones estimated in EU and the US used.

Modelled deaths (green line), multiplied by 5 (red line), and death notification data (blue line) between 6 January 2022 and 25 February 2022.

The results of sensitivity analysis on mask use, based on the last reported vaccination rates (39.3% of the 15+age group with two doses and 6.3% of the 60+with 3 doses), are shown in Figs.3 and 4. The epidemic forecast is shown in Fig.3, with hospitalization and ICU daily bed requirements in Fig.4. In each scenario, the epidemic peak was expected to be at the start of April 2022.

Number of daily new cases (incidence), cumulative cases, and cumulative deaths in the scenario with 39.3% of the 15+age group with two doses and 6.3% of the 60+with 3 doses, varying mask use coverage (0%, 50%, 80%) with 60% effectiveness, from 6 January to 14 April 2022.

Hospitalization (H) and ICU beds used over time, keeping the last vaccination coverage notified (39.3% of the 15+age group with two doses and 6.3% of the 60+with 3 doses) and varying mask use coverage (0%, 50%, 80%), from 6 January to 5 June 2022.

The outbreak peaks at about 3.7, 2.3, and 1.4 million cases, with a total of almost 90%, 80%, and 70% of the population being infected at the end of the outbreak, with 0%, 50%, and 80% of the population using masks, respectively (Fig.3). Figure4 shows that the maximum number of daily hospital beds required at the peak is estimated to be about 140, 103, and 69 thousand in scenarios of varying mask use, with a total of almost 300,000 beds available in Ukraine before the war started. The number of daily ICU beds required at the peak is estimated to be about 21, 15, and 10 thousand with 0%, 50%, and 80% mask use.

The results of the sensitivity analysis on vaccination coverage are shown in Figs.5 and 6. Figure5 shows the epidemic forecast and Fig.6, the hospitalization and ICU daily bed requirement with mask use at 50% and vaccination rates increased from 39.3% to 60% and 80%.

Case incidence, cumulative cases, and deaths in the scenario with 50% of the population using masks and varying the vaccination coverage, for 2 doses (v2) and three doses (v3), from 6 January to 16 April 2022.

Hospitalization (H) and ICU beds used over time, with 50% of the population using masks and varying the vaccination coverage for two (v2) and three doses (v3), from 6 January to 5 June 2022.

The outbreak peaks at about 2.3, 2.1, and 1.8 million cases, with a total of about 80%, 76%, and 74% of the population being infected at the end of the outbreak, at the three different vaccination scenarios (Fig.5). The maximum number of hospital beds required at the peak is estimated to be about 103, 80, and 56 thousand in each scenario, while requirements for ICU beds have been estimated to be about 15, 11, and 7 thousand (Fig.6).

From the base case scenario, the model shows increasing mask-wearing from 50% (base-case) to 80% could result in a 17% reduction in cases (from a total of 33,432,800 at 50% to 28,006,300 at 80%) and a 30% reduction in deaths (from 56,028 to 39,241). If vaccine coverage is increased from 39.3% and 6.3% with two and three doses respectively (base-case) to 60% of people aged 15+with two doses and 9.6% of people aged 60+with three doses, the reduction in cases and deaths could have been 3% (from 33,432,800 to 32,365,700) and 28% (from 56,028 to 39,867) respectively. However, when comparing the results of increasing mask use at 80% with the scenario where 80% and 12.8% of the population are vaccinated with two and three doses respectively, we found that high mask use results in a lower cumulative total number of cases (about 28 million) compared with high two doses vaccination coverage (about 31 million), but a higher number of total death (about 38,000 against 23,000). When testing if results were consistent in the case of only poor-quality masks (40% instead of 60% effectiveness) being available, we found that increasing mask use from 50% to 80% could have reduced cases and deaths by 6.1% (from 35,246,400 at 50% to 33,070,800 at 80% mask use) and 11.3% respectively (from 65,758 to 58,335). If vaccine coverage was increased to 60% with two doses and 9.6% of people aged 60+with three doses, the reduction in cases and deaths could have been respectively 2.3% (from 35,246,400 to 34,443,600) and 25.6% (from 65,758 to 48,781).

Continued here:

Impact of vaccine coverage and disruption to health services on COVID-19 in Ukraine | Scientific Reports - Nature.com

As COVID-19 ticks up in some places, US health officials recommend a fall vaccination campaign – The Associated Press

June 29, 2024

NEW YORK (AP) With fresh COVID-19 cases bubbling up in some parts of the country, health officials are setting course for a fall vaccination campaign.

The Centers for Disease Control and Prevention on Thursday recommended new shots for all Americans this fall.

Officials acknowledged the need for shots is not as dire as it was only a few years ago. Most Americans have some degree of immunity from being infected, from past vaccinations or both. COVID-19 deaths and hospitalizations last month were at about their lowest point since the pandemic first hit the United States in 2020.

But immunity wanes, new coronavirus variants keep emerging and there are still hundreds of COVID-19-associated deaths and thousands of hospitalizations reported each week.

Whats more, health officials have reported upticks this month in COVID-19-associated emergency room visits and hospitalizations, and a pronounced increase in positive test results in the southwestern U.S.

Its not clear whether thats a sign of a coming summer wave which has happened before or just a blip, said Lauren Ancel Meyers of the University of Texas, who leads a research team that tracks COVID-19.

Well have to see what happens in the coming weeks, she said.

Earlier this month, the Food and Drug Administration following the guidance of its own panel of expert advisers told vaccine manufacturers to target the JN.1 version of the virus. But a week later, the FDA told manufacturers that if they could still switch, a better target might be an offshoot subtype called KP.2.

At a Thursday meeting at the CDC in Atlanta, infectious disease experts unanimously recommended the updated vaccines for Americans age 6 months and older. The CDC director signed off on the recommendation later in the day. The shots are expected to become available in August and September.

Health officials have told Americans to expect a yearly update to COVID-19 vaccines, just like they are recommended to get a new shot each fall to protect against the latest flu strains.

But many Americans arent heeding the CDCs advice.

As of last month, less than one-quarter of U.S. adults and 14% of children were up to date in their COVID shots. Surveys show shrinking percentages of Americans think COVID-19 is a major health threat to the U.S. population, and indicate that fewer doctors are urging patients to get updated vaccines.

CDC officials on Thursday presented recent survey information in which about 23% of respondents said they would definitely get an updated COVID-19 shot this fall, but 33% said they definitely would not.

Meanwhile, the CDCs Bridge Access Program which has been paying for shots for uninsured U.S. adults is expected to shut down in August because of discontinued funding. The program paid for nearly 1.5 million doses from September to last month.

It is a challenge with this program going away, said the CDCs Shannon Stokley.

About 1.2 million U.S. COVID-associated deaths have been reported since early 2020, according to the CDC. The toll was most intense in the winter of 2020-2021, when weekly deaths surpassed 20,000. About 1 out of every 100 Americans ages 75 and older were hospitalized with COVID in the last four years, CDC officials said Thursday.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Science and Educational Media Group. The AP is solely responsible for all content.

View original post here:

As COVID-19 ticks up in some places, US health officials recommend a fall vaccination campaign - The Associated Press

COVID-19 continues to have deadly impacts on public health – Courier Journal

June 29, 2024

courier-journal.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.

Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on courier-journal.com

Read more:

COVID-19 continues to have deadly impacts on public health - Courier Journal

Trump Once Suggested Injecting Disinfectant Could Be COVID-19 Treatment? – Snopes.com

June 29, 2024

Claim:

Former U.S. President Donald Trump once said, with regard to possible medical treatments for COVID-19: "And then I see the disinfectant, where it knocks it out in a minute. One minute. And is there a way we can do something like that, by injection inside or almost a cleaning."

During the first presidential debate of the 2024 presidential cycle, U.S. President Joe Biden referenced a claim that has repeatedly been spread regarding former President Donald Trump and his response to the COVID-19 pandemic.

"We had an economy that was in free fall," Biden saidduring his opening remarks on June 27. "The pandemic was so badly handled. Many people were dying. All he said was it's not that serious, just inject a little bleach in your arm. You'll be all right."

The claim has spread since April 2020, when Trump's remarks during a White House press briefing spread online. Publications like Politico reportedTrump suggested injecting bleach. Biden himself has also repeated the claim, with PolitiFactfact-checking comments he made about it in March 2024.

We previouslyfact-checked the claim, where we found Trump had discussed injecting "disinfectant" to fight COVID-19. Here's the official White House transcriptof Trump's remarks (emphasis added) from April 2020:

TRUMP: ...And then I see the disinfectant, where it knocks it out in a minute. One minute. And is there a way we can do something like that, by injection inside or almost a cleaning. Because you see it gets in the lungs and it does a tremendous number on the lungs. So it would be interesting to check that. So, that, you're going to have to use medical doctors with. But it sounds it sounds interesting to me.

Trump saidhe was "asking a question sarcastically" to reporters "just to see what would happen" the day after the press briefing. The Trump campaign has continuouslysated what he said was taken out of context, telling PolitiFact what Biden said in March 2024 was "more misinformation and lies."

RB, the maker of Lysol, issued a statement after Trump made his remarks that said disinfectantscould not be used as a treatment for COVID-19.

To get more fact-checks of what Biden and Trump said during the debate, you can find our fact-checking of what happened which we covered in real timehere.

CNN Staff. "READ: Biden-Trump Debate Rush Transcript | CNN Politics." CNN, 28 June 2024, https://www.cnn.com/2024/06/27/politics/read-biden-trump-debate-rush-transcript/index.html.

Evon, Dan. "Did Trump Suggest Injecting Disinfectant Could Be COVID-19 Treatment?" Snopes, 24 Apr. 2020, https://www.snopes.com//fact-check/trump-disinfectants-covid-19/.

McGraw, Meredith & Stein, Sam. "It's Been Exactly One Year Since Trump Suggested Injecting bleach. We've Never Been the Same." Politico,https://www.politico.com/news/2021/04/23/trump-bleach-one-year-484399. Accessed 28 June 2024.

O'Kane, Caitlin. "Lysol Maker Warns against Injecting and Drinking Disinfectants as a Coronavirus Treatment." CBS News. 24 Apr. 2020, https://www.cbsnews.com/news/lysol-injecting-trump-disinfectants-coronavirus-treatment/.

"Remarks by President Trump, Vice President Pence, and Members of the Coronavirus Task Force in Press Briefing." Trump White House Archives, 23 April 2020,https://trumpwhitehouse.archives.gov/briefings-statements/remarks-president-trump-vice-president-pence-members-coronavirus-task-force-press-briefing-31/. Accessed 28 June 2024.

Snopes Staff. "Fact-Checking the 2024 Presidential Debate." Snopes, 27 June 2024, https://www.snopes.com//news/2024/06/27/presidential-debate-live-updates/.

Specht, Paul. "Biden Exaggerates Trump's Pandemic Comments about Disinfectants, UV Light." PolitiFact, https://www.politifact.com/factchecks/2024/mar/28/joe-biden/biden-exaggerates-trumps-pandemic-comments-about-d/. Accessed 28 June 2024.

Timm, Jane C. "Trump Says He Was Being Sarcastic with Comments about Injecting Disinfectants." NBC News, 24 Apr. 2020, https://www.nbcnews.com/politics/donald-trump/trump-says-he-was-being-sarcastic-comments-about-injecting-disinfectants-n1191991.

Visit link:

Trump Once Suggested Injecting Disinfectant Could Be COVID-19 Treatment? - Snopes.com

Senegal says it detected Covid-19 in returning Hajj pilgrims – Africanews English

June 26, 2024

Senegal says it has detected Covid-19 in dozens of pilgrims returning from their Hajj journey in Mecca. From tests conducted at Dakar's Blaise Diagne International Airport, 78 cases of Covid-19 were recorded.

Senegal's health ministry said the results are not surprising. It said returning pilgrims had been advised to wear masks and self-isolate.

Authorities said they have stepped up surveillance.

Saudi officials on Sunday said more than 1,300 people died during this years Hajj pilgrimage. They blamed the fatalities on extremely high summer temperatures.

During events such as the symbolic stoning of the pillars, many people crowd in the same place with no allowance for social distancing. There have been deadly stampedes in the past.

More than 1.83 million Muslims performed Hajj in 2024. Senegal alone sent 12,900 pilgrims.

View original post here:

Senegal says it detected Covid-19 in returning Hajj pilgrims - Africanews English

Summer COVID bump intensifies in L.A. and California, fueled by FLiRT variants – Los Angeles Times

June 26, 2024

The new COVID-19 subvariants collectively nicknamed FLiRT are continuing to increase their dominance nationwide, fueling a rise in cases in Los Angeles County and growth in the coronavirus levels seen in California wastewater.

Taken together, the data point to a coronavirus resurgence in the Golden State one that, while not wholly unexpected given the trends seen in previous pandemic-era summers, has arrived earlier and is being driven by even more transmissible strains than those previously seen.

It remains unclear how bad the COVID situation may get this summer, however. Doctors have said that by the Fourth of July, we may have a better feel for how the rest of the season will play out.

The U.S. Centers for Disease Control and Prevention estimates that the FLiRT subvariants officially known as KP.3, KP.2 and KP.1.1 make up a combined 62.9% of specimens nationwide for the two-week period ending Saturday. Thats up from 45.3% a month ago.

Experts say the new subvariants are more contagious than the winters dominant subvariant, JN.1.

California is now one of 15 states with high or very high coronavirus levels in sewage, according to the CDC. Those states are generally in the West and the South, as well as New England. Besides California, they are Alaska, Colorado, Connecticut, Florida, Hawaii, Idaho, Missouri, Nevada, New Hampshire, New Mexico, Tennessee, Texas, Utah and Wyoming.

Coronavirus levels in California wastewater overall have sharply increased since early May, a contrast to national trends, which indicate a slower rise. Californias latest weekly wastewater viral activity level was near the peak seen last summer.

In Santa Clara County, Northern Californias most populous, the levels in wastewater are considered high across a wide swath of Silicon Valley, from San Jos to Palo Alto.

Coronavirus levels in L.A. County wastewater have remained generally stable after rising last month. For the week ending June 8, the most recent available, levels in sewage were at 15% of the peak from the winter of 202223 up from 13% the prior week, but down slightly from 16% the week before that. Last summer peaked near the end of the season, when levels in sewage were at 38% of the 202223 winter height.

Reported COVID-19 cases continue to rise, though. For the seven-day period that ended June 16, there were an average of 154 per day reported in L.A. County, up from 121 the prior week. Reported cases are an undercount, as they indicate only tests done at medical facilities, and dont include at-home tests. Nor do they reflect that far fewer people are testing for COVID when theyre sick.

The daily average number of people with COVID in L.A. County hospitals is also ticking up. There were an average of 138 per day for the week that ended June 15, up from 126 the week before.

COVID deaths remain stable, at fewer than one per a day, on average, for the week that ended May 28.

The percentage of COVID tests at Californias medical facilities that are coming back with positive results continues to climb. For the week that ended June 17, 7.5% of statewide COVID tests came back positive, well above the 3.1% rate from a month ago. Last summers peak was 13.1%, recorded at the end of August.

The California Department of Public Health in June updated its guidance for older adults, especially those with weakened immune systems. Officials urged older people to stay up to date on vaccines, seek medication if sickened with COVID, and to consider extra precautions, such as wearing a mask in crowded indoor areas, opening windows and doors to increase ventilation, staying away from sick people, washing their hands often, and covering up coughs and sneezes.

The increases in certain coronavirus tracking data come as the U.S. Food and Drug Administration in mid-June released new advice for vaccine manufacturers. In a June 13 statement, the agency urged that manufacturers, if feasible, design this autumns vaccine formula against KP.2 one of the FLiRT subvariants instead of its parent, JN.1.

The new recommendation overrides guidance from just a week earlier, when the agency had advised the vaccines to be designed against JN.1.

This change is intended to ensure that the COVID-19 vaccines (2024-2025 formula) more closely match circulating SARS-CoV-2 strains, the FDA said in a statement, referring to the formal name of the COVID-19 virus.

By this autumn, the prevailing COVID subvariant will probably be closer to KP.2 than they would have been, perhaps, to JN.1, said Dr. Peter Marks, director for the FDAs Center for Biologics Evaluation and Research, in a press briefing Friday.

The mRNA-based vaccines, made by Pfizer and Moderna, will be able to produce shots this fall for KP.2. But the protein-based vaccine, made by Novavax, will remain designed against JN.1 as mRNA vaccine manufacturing can be done more quickly, Marks said.

What you can do when youre making a protein-based vaccine versus an mRNA vaccine is different in terms of the agility to react to whats coming up, Marks said. Still, the difference between getting a vaccine designed against the newer KP.2 subvariant versus the slightly older JN.1 subvariant will probably not result in that big of a difference.

Were not going to have a preference, Marks said, in terms of making a recommendation of the Pfizer or Moderna vaccine over Novavax. The best vaccine for going into this fall season is the one that you put in your arm.

Marks said a vaccine designed against KP.2 perhaps brings a little benefit over one against JN.1. By essentially using the freshest update, we hope to provide protection immunity that will last longer, Marks said, into the late autumn and the winter.

Its like trying to give people the greatest edge, right? The one-hundredth of a second extra that you win [a race] with, Marks said. But I think the most important thing for people to know is, either way, either of these is perfectly good to get.

Federal officials expressed hope that the COVID vaccine would be made available earlier this year than in 2023. Last years rollout was complicated because the updated COVID vaccine came out slightly later than the seasonal flu shots, making it more difficult for people to get both vaccinations at the same visit if they wouldve preferred that.

COVID-19 continues to remain a disease to guard against, doctors say. About 45,000 COVID deaths have been reported since Oct. 1 nationally, and doctors say those most at risk are older and immunocompromised people who havent received an up-to-date vaccination.

This isnt just going away into the night. Its hanging around, Marks said.

Read more here:

Summer COVID bump intensifies in L.A. and California, fueled by FLiRT variants - Los Angeles Times

COVID is bouncing back this summer. Here’s what to know – Los Angeles Times

June 26, 2024

Good morning. Its Tuesday, June 25. Heres what you need to know to start your day.

Newsletter

You're reading the Essential California newsletter

Our reporters guide you through our biggest news, features and recommendations every morning

Enter email address

Sign Me Up

You may occasionally receive promotional content from the Los Angeles Times.

Summer just started, but Californias not-too-surprising seasonal COVID bump is already going strong, driven by the more transmissible FLiRT variants.

KP.2, KP.3 and KP.1.1 given the acronym FLiRT based on the amino acid changes that led to the strains mutations account for an estimated 63% of infections, according to the U.S. Centers for Disease Control and Prevention. Thats up from about 20% in late April.

Coronavirus levels found in Californias wastewater have risen sharply since early May and stand notably higher than the rest of the U.S. The average number of cases reported in Los Angeles County shot to 154 per day for the most recent seven-day reporting period, up about 27% from the previous week. But those figures are an undercount since they dont include at-home tests (or the people who catch COVID but dont test at all).

Taken together, the data point to a coronavirus resurgence in the Golden State, The Times Rong-Gong Lin II reported this week. One that, while not wholly unexpected given the trends seen in previous pandemic-era summers, has arrived earlier and is being driven by even more transmissible strains than those previously seen.

More people in L.A. County hospitals are testing positive for COVID, though deaths are keeping stable at fewer than one per a day, on average.

California is one of 15 states with high or very high coronavirus levels in sewage, according to the CDC. Just four days into summer, state levels are already nearing last summers peak.

Health officials say it wont be a shock to see more COVID cases this summer, as seen in previous summers. More traveling, more gatherings on weekends and holidays and more congregating inside to escape the heat increase the chance of catching the increasingly infectious virus.

So how much worse could it get? Thats still TBD, Lin noted.

Doctors have said that by the Fourth of July, we may have a better feel for how the rest of the season will play out, he wrote.

As for fall vaccines, the mRNA-based versions produced by Pfizer and Moderna should be designed against the KP.2 variant, though Novavaxs protein-based vaccine will target its parent, JN.1.

Because the FLiRT subvariants are more easily transmitted, doctors advise those at higher risk for severe COVID-19 infections to take precautions. Those include:

The strongest risk factor for severe COVID-19 continues to be age, according to the CDC. People with certain underlying medical conditions including asthma, cancer, diabetes and serious heart conditions are also at heightened risk.

A pro-Israeli counterprotester leans in as she speaks to pro-Palestinian protesters near Adas Torah synagogue in the Pico-Robertson neighborhood in Los Angeles on Sunday.

(Zo Cranfill / Los Angeles Times)

Crime and courts

More big stories

Get unlimited access to the Los Angeles Times. Subscribe here.

Indigenous communities in Mexico have long considered psychedelic mushrooms to be intermediaries to the spiritual world.

(Alejandra Rajal / For the Times)

Mexico may legalize magic mushrooms. Will this traditional medicine lose its meaning? Mexico may legalize the use of magic mushrooms providing there is an Rx or an Indigenous healer. Will the traditional medicine lose its meaning as its use is expanded?

Other great reads

How can we make this newsletter more useful? Send comments to essentialcalifornia@latimes.com.

The exterior of Arbys in Huntington Beach. Its one of the few remaining locations that still features a chuck-wagon building.

(Jenn Harris / Los Angeles Times)

Going out

Staying in

Show us your favorite place in California! Were running low on submissions. Send us photos that scream California and we may feature them in an edition of Essential California.

A group from Contact in the Desert, a UFO convention, visits Giant Rock. The boulder is a gathering place for people seeking to commune with extraterrestrials and others seeking to party.

(Gina Ferazzi / Los Angeles Times)

Todays great photo is from Times photographer Gina Ferazzi from a seven-story boulder on federal land that has become a tinderbox of tensions over who gets to enjoy this patch of Mojave Desert, which has rapidly gentrified since the COVID-19 pandemic.

Have a great day, from the Essential California team

Ryan Fonseca, reporter Kevinisha Walker, multiplatform editor and Saturday reporter Christian Orozco, assistant editor Stephanie Chavez, deputy metro editor Karim Doumar, head of newsletters

Check our top stories, topics and the latest articles on latimes.com.

More:

COVID is bouncing back this summer. Here's what to know - Los Angeles Times

Page 15«..10..14151617..2030..»